Compare Credo Technology Group Holding Ltd (CRDO) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Humana Inc — how do they compare? Credo Technology Group Holding Ltd trades at $215.99 (market cap $39.82B), while Humana Inc trades at $433 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.91% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Humana Inc for 51 Days on average.
| CRDO | HUM | |
|---|---|---|
Market Cap | $39.82B | $46.49B |
Volume | 9,451,558 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $302.52 | $409.85 |
52-Week Low | $87.81 | $163.67 |
Typical Hold Time | 22 Days | 51 Days |
Enterprise Value | $39.08B | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $216.55, down 1.57% on the day, but maintains strong bullish momentum with triple-digit revenue growth driven by AI infrastructure demand. The stock shows robust fundamentals with 33.83% net margins and consistent earnings beats, though valuation metrics remain elevated with a P/E of 74.6. Technical indicators suggest bullish momentum with support at $204 and resistance at $222.
Outlook remains positive given explosive AI-driven growth and strong analyst support (87.5% buy ratings), but premium valuation and customer concentration present execution risks. The consensus price target of $267.33 implies 23% upside potential from current levels, supported by expanding optical product offerings and hyperscaler relationships.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
